This research identifies IRE1a as a potential therapeutic target in pancreatic ductal adenocarcinoma, suggesting its role in the unfolded protein response.
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with limited therapeutic options and poor prognosis. Current treatment options remain limited, urging for better understanding of the molecular mechanisms in PDAC. Cells from PDAC tumors face significant ER stress due to increased secretory demand, oncogenic activation and the tumor microenvironment. The unfolded protein response (UPR), a cellular stress response that helps manage unfolded proteins in the endoplasmic reticulum (ER) is of paramount importance in this context. The Inositol requiring enzyme 1 alpha (IRE1a) arm of UPR has emerged as a promising target for therapeutic intervention. However, its role in PDAC remains insufficiently explored.
No takes yet. Share an insight, caveat, or question.
Sarkar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: